ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties

Guoli Xiong,Zhenxing Wu,Jiacai Yi,Li Fu,Zhijiang Yang,Changyu Hsieh,Mingzhu Yin,Xiangxiang Zeng,Chengkun Wu,Aiping Lu,Xiang Chen,Tingjun Hou,Dongsheng Cao

DOI: https://doi.org/10.1093/nar/gkab255

IF: 14.9

2021-04-24

Nucleic Acids Research

Abstract:Abstract Because undesirable pharmacokinetics and toxicity of candidate compounds are the main reasons for the failure of drug development, it has been widely recognized that absorption, distribution, metabolism, excretion and toxicity (ADMET) should be evaluated as early as possible. In silico ADMET evaluation models have been developed as an additional tool to assist medicinal chemists in the design and optimization of leads. Here, we announced the release of ADMETlab 2.0, a completely redesigned version of the widely used AMDETlab web server for the predictions of pharmacokinetics and toxicity properties of chemicals, of which the supported ADMET-related endpoints are approximately twice the number of the endpoints in the previous version, including 17 physicochemical properties, 13 medicinal chemistry properties, 23 ADME properties, 27 toxicity endpoints and 8 toxicophore rules (751 substructures). A multi-task graph attention framework was employed to develop the robust and accurate models in ADMETlab 2.0. The batch computation module was provided in response to numerous requests from users, and the representation of the results was further optimized. The ADMETlab 2.0 server is freely available, without registration, at https://admetmesh.scbdd.com/.

biochemistry & molecular biology

What problem does this paper attempt to address?

The problem this paper attempts to address is the high failure rate of candidate compounds in the drug development process due to poor pharmacokinetics and toxicity. Specifically, the authors point out that Absorption, Distribution, Metabolism, Excretion, and Toxicity, collectively known as ADMET properties, are crucial for the success of a drug. However, in traditional drug development workflows, these properties are usually evaluated only after determining the compound's efficacy against a specific target, leading to the late discovery of adverse side effects. This often necessitates redesigning the molecule or even terminating the project. Therefore, this study aims to improve the efficiency and success rate of drug development by developing a comprehensive and accurate online platform, ADMETlab 2.0, to predict the ADMET properties of compounds early in the process.

ADMETlab 2.0 not only supports more ADMET-related endpoints (approximately twice as many as the previous version) but also employs a Multi-task Graph Attention (MGA) framework to build robust and accurate prediction models. Additionally, the platform provides a batch calculation module and optimizes the result presentation to better meet user needs. Overall, the goal of ADMETlab 2.0 is to provide medicinal chemists with a powerful tool to eliminate undesirable compounds during the drug design and optimization stages and to obtain timely feedback on ADMET information.